Kim et al. compared patients with a high-CD133-expression HCC and those with a low CD133 expression and found that the progression-free survival (PFS) after sorafenib therapy was 4 months vs. 5.5 months, respectively [37]. Here, PROM1 is linked to hepatocellular carcinoma.